CRISPRi Screening Identifies Essential E. coli Virulence Factors for Placental Barrier Breach in a Maternal–Fetal Infection Model
International Journal of Molecular Sciences · 09.02.2026 · 27 (4) · 1661
DOI: 10.3390/ijms27041661 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.02.2026. Verfasst von Xiaochen Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Capital Institute of Pediatrics, Beijing 100020, China. Hauptthemen laut MEDLINE: Virulence Factors, Escherichia coli, Escherichia coli Infections, Placenta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Cross-cooperation project of Beijing Science and Technology New Star Program.
Abstract (Originalsprache)
Early-onset neonatal sepsis caused by Escherichia coli (E. coli) threatens neonates’ lives due to the pathogen’s high virulence and multidrug resistance. The mechanisms that enable its placental barrier breach are poorly understood. Using a clinically isolated ST95 ExPEC strain from a neonatal sepsis case, along with a pregnant rat model and an in vitro placental barrier model, we performed CRISPR interference screening. This screen targeted 264 virulence factor genes and identified virulence factors for motility, iron acquisition, hemolysin secretion, and adherence/invasion as critical. We demonstrated that hlyB is essential for uterine infection, and we elucidated a mechanism for ibeA that facilitates syncytial trophoblast cell layer penetration by interacting with the host receptor(s) PSF/VIM to enhance bacterial internalization. Host cells countered ibeA+ E. coli infection via a novel host defense pathway involving upregulation of ASPHD1. This study systematically mapped the virulence factors required for E. coli placental translocation and delineated key host–pathogen interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neonatology, Capital Institute of Pediatrics, Beijing 100020, China.
- Capital Center for Children's Health, Capital Medical University, Yabaolu No. 2, Chaoyang District, Beijing 100020, China.
- Department of Neonatology, Capital Institute of Pediatrics, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
ORCID-Profile: Xiaochen Cai, Peicen Zou, Ruiqi Xiao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Cross-cooperation project of Beijing Science and Technology New Star Program
- High Level Public Health Technical Personnel Construction Project
- Research Foundation of Capital Institute of Pediatrics
- Beijing Chaoyang District Postdoctoral Research Foundation 2024
- Cross-cooperation project of the Beijing Science and Technology New Star Program
- Beijing Chaoyang District Postdoctoral Research Foundation
Zitieren
APA
Cai, X., Liang, X., Zou, P., Xiao, R., & Wang, Y. (2026). CRISPRi Screening Identifies Essential E. coli Virulence Factors for Placental Barrier Breach in a Maternal–Fetal Infection Model. International Journal of Molecular Sciences, 27(4), 1661. https://doi.org/10.3390/ijms27041661
Vancouver
Cai X, Liang X, Zou P, Xiao R, Wang Y. CRISPRi Screening Identifies Essential E. coli Virulence Factors for Placental Barrier Breach in a Maternal–Fetal Infection Model. International Journal of Molecular Sciences. 2026;27(4):1661. doi:10.3390/ijms27041661
BibTeX
@article{Cai2026,
author = {Cai, Xiaochen and Liang, Xiao and Zou, Peicen and Xiao, Ruiqi and Wang, Yajuan},
title = {CRISPRi Screening Identifies Essential E. coli Virulence Factors for Placental Barrier Breach in a Maternal–Fetal Infection Model},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {4},
pages = {1661},
doi = {10.3390/ijms27041661}
}
EUVIMED